HUZALDA Trademark

Trademark Overview

On Tuesday, March 9, 2021, a trademark application was filed for HUZALDA with the United States Patent and Trademark Office. The USPTO has given the HUZALDA trademark a serial number of 90567879. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Tuesday, June 25, 2024. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The HUZALDA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cancer, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, pain, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for use in hematology
huzalda

General Information

Serial Number90567879
Word MarkHUZALDA
Filing DateTuesday, March 9, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 9, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cancer, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, infectious, inflammatory, menopausal, neurological, pain, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for use in hematology

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 8, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Friday, March 12, 2021NEW APPLICATION ENTERED
Tuesday, June 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 1, 2021ASSIGNED TO EXAMINER
Thursday, October 7, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 20, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 9, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 9, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, November 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, November 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, November 10, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, November 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, January 4, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 4, 2022SOU EXTENSION 1 FILED
Monday, August 8, 2022ABANDONMENT - NO USE STATEMENT FILED
Monday, August 8, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, August 9, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, August 9, 2022PETITION TO REVIVE-GRANTED
Tuesday, August 9, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, August 9, 2022NOTICE OF REVIVAL - E-MAILED
Thursday, September 1, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 1, 2022SOU EXTENSION 1 GRANTED
Friday, September 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 4, 2023SOU EXTENSION 2 FILED
Wednesday, January 4, 2023SOU EXTENSION 2 GRANTED
Friday, January 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 21, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, June 21, 2023SOU EXTENSION 3 FILED
Wednesday, June 21, 2023SOU EXTENSION 3 GRANTED
Friday, June 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 5, 2024ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 29, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, February 29, 2024PETITION TO REVIVE-GRANTED
Thursday, January 4, 2024SOU EXTENSION 4 FILED
Monday, February 5, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, February 29, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, February 29, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, February 29, 2024NOTICE OF REVIVAL - E-MAILED
Tuesday, June 25, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 25, 2024SOU EXTENSION 5 GRANTED
Tuesday, June 25, 2024SOU EXTENSION 5 FILED
Thursday, March 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 20, 2024SOU EXTENSION 4 GRANTED

Related Keywords

huzalda preparations pharmaceutical respiratory pain neurological urogenital menopausal urological hematology disorders